Hostname: page-component-848d4c4894-xfwgj Total loading time: 0 Render date: 2024-07-01T12:38:19.786Z Has data issue: false hasContentIssue false
  • English
  • Français

Marfan syndrome in a paediatric cohort: the importance of family history

Published online by Cambridge University Press:  17 March 2023

Laia Brunet-Garcia Open the ORCID record for Laia Brunet-Garcia [Opens in a new window] ,
Angela Lopez Sainz  and
Juan Manuel Carretero Bellon
Laia Brunet-Garcia
Affiliation:
Department of Paediatric Cardiology, Consorci Sanitari del Maresme, Hospital de Mataró, Barcelona, Spain
Angela Lopez Sainz
Affiliation:
Department of Cardiology, Hospital Clínic de Barcelona, Barcelona, Spain
Juan Manuel Carretero Bellon*
Affiliation:
Department of Paediatric Cardiology, Hospital Sant Joan de Déu, Barcelona, Spain Department of Paediatric Cardiology, Hospital Universitari Joan XXIII, Universitat Rovira i Virgili, Tarragona, Spain
*
Author for correspondence: Juan Manuel Carretero Bellon, Department of Paediatric Cardiology, Hospital Sant Joan de Déu, Barcelona, Spain. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Marfan syndrome is a rare connective tissue disorder secondary to mutations in the FBN1 gene, characterised by skeletal, ocular, and cardiovascular manifestations. We present an extensive cohort of paediatric patients with Marfan syndrome highlighting the vital importance of promptly referring paediatric first-degree relatives of Marfan syndrome paediatric patients to a tertiary hospital as our results confirm that they are at higher risk of aortic dilatation.

Keywords

Connective tissue disorderMarfan syndromeaortic dilatationaortic surgeryfamily history
Type
Brief Report
Information
Cardiology in the Young , Volume 33 , Issue 9 , September 2023 , pp. 1733 - 1734
Check for updates
Copyright
© The Author(s), 2023. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Erbel, R, Aboyans, V, Boileau, C, et al. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014; 35: 2873–2926.Google ScholarPubMed
Loeys, BL, Dietz, HC, Braverman, AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010; 47: 476–485.CrossRefGoogle ScholarPubMed
Meester, JAN, Verstraeten, A, Schepers, D, Alaerts, M, Van, LL, Loeys, BL. Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome. Ann Cardiothorac Surg. 2017; 6: 582–594.CrossRefGoogle ScholarPubMed
Lacro, RV, Dietz, HC, Sleeper, LA, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med. 2014; 371: 2061–2071.CrossRefGoogle Scholar
Hiratzka, LF, Bakris, GL, Beckman, JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary: a report of the american college of cardiology foundation/american heart association task force on pra. Circulation. 2010; 121: 1544–1579.Google Scholar
Silverman, DI, Gray, J, Roman, MJ, et al. Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. J Am Coll Cardiol. 1995; 26: 1062–1067.CrossRefGoogle ScholarPubMed
Ekhomu, O, Naheed, ZJ. Aortic involvement in pediatric Marfan syndrome: a review. Pediatr Cardiol. 2015; 36: 887–895.CrossRefGoogle ScholarPubMed